- Home
- FGL vs NRXP Comparison
FGL vs NRXP Comparison
Compare FGL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGL
- NRXP
- Stock Information
- Founded
- FGL 2021
- NRXP 2015
- Country
- FGL Malaysia
- NRXP United States
- Employees
- FGL N/A
- NRXP N/A
- Industry
- FGL
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- FGL
- NRXP Health Care
- Exchange
- FGL NYSE
- NRXP Nasdaq
- Market Cap
- FGL 25.4M
- NRXP 58.5M
- IPO Year
- FGL 2024
- NRXP N/A
- Fundamental
- Price
- FGL $1.21
- NRXP $2.81
- Analyst Decision
- FGL
- NRXP Strong Buy
- Analyst Count
- FGL 0
- NRXP 4
- Target Price
- FGL N/A
- NRXP $28.50
- AVG Volume (30 Days)
- FGL 345.2K
- NRXP 134.9K
- Earning Date
- FGL 08-05-2025
- NRXP 08-13-2025
- Dividend Yield
- FGL N/A
- NRXP N/A
- EPS Growth
- FGL N/A
- NRXP N/A
- EPS
- FGL N/A
- NRXP N/A
- Revenue
- FGL $20,205,441.00
- NRXP N/A
- Revenue This Year
- FGL N/A
- NRXP N/A
- Revenue Next Year
- FGL N/A
- NRXP $230.95
- P/E Ratio
- FGL N/A
- NRXP N/A
- Revenue Growth
- FGL N/A
- NRXP N/A
- 52 Week Low
- FGL $0.66
- NRXP $1.10
- 52 Week High
- FGL $5.26
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- FGL N/A
- NRXP 35.57
- Support Level
- FGL N/A
- NRXP $2.89
- Resistance Level
- FGL N/A
- NRXP $3.15
- Average True Range (ATR)
- FGL 0.00
- NRXP 0.14
- MACD
- FGL 0.00
- NRXP -0.04
- Stochastic Oscillator
- FGL 0.00
- NRXP 7.27
About FGL FOUNDER GROUP LTD
Founder Group Ltd is a solar solutions provider in Malaysia, offering end-to-end services for commercial and industrial sectors, as well as large-scale solar power projects, encompassing project design, engineering, and comprehensive project management. Its focus is on two key segments: large-scale solar projects and commercial and industrial (C&I) solar projects. Large-scale solar projects are utility scale solar PV power plants with installed generating capacity of 1 MWac or more. C&I projects are smaller scale solar projects where the solar PV systems are installed on rooftops and are designed to generate electricity for commercial and industrial properties for their own consumption, such as factories, warehouses and commercial stores. Its revenue is derived from Malaysia.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.